RxDoctor Payments Data

Valerie Flynn

Dermatology · Sioux Falls, SDNPI 1992996771

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,495 of the $3,003 with a category attached, or 83.1%. 18 manufacturers reported payments, led by AbbVie at 30.3% of the total.

$3,003in general payments, 2019–2025

Across 188 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$910
  • Johnson & Johnson$777
  • Regeneron Healthcare Solutions, Inc.$386
  • Lilly USA, LLC$164
  • Amgen$157
  • Sun Pharmaceutical Industries Inc.$147
  • plus $462 from 12 others

What the payments were for

  • Food & beverage$2,49583%
  • Education$50817%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,003 in reported general payments places this provider in the 75th percentile of 44 dermatology providers in South Dakota.

See all dermatology providers in South Dakota

Medicare billing

Part B allowed, 2024
$164,392
Medicare patients
735
Services billed
3,964

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa13$254,732
TremfyaGuselkumab18$231,776
OtezlaApremilast54$227,055
Cosentyx Sensoready (2 Pens)Secukinumab22$156,474
Taltz AutoinjectorIxekizumab13$79,511
JubliaEfinaconazole13$9,726
Dapsone20$4,383
Clindamycin Phosphate53$2,451
Clobetasol Propionate26$2,003
MethotrexateMethotrexate Sodium58$1,387
Mometasone Furoate61$1,242
Desonide22$1,164
Doxycycline Hyclate58$1,089
Fluocinonide23$822
Spironolactone39$581

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$777$231,77618 claims
AmgenOtezla$157$227,05554 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 44 dermatology providers in South Dakota.

Other dermatology in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →